Berubicin, a powerful anthracycline, may be able to access and treat glioblastoma multiforme (GBM) cells in the brain. In phase 1 clinical trials, 44% of patients showed significant anti-tumor activity, according to a CNS Pharmaceuticals press release.
GBM is the most common type of brain cancer, and has a poor prognosis. More than 12,000 cases of GBM are projected in the US for 2018 alone, and these patients only have a median survival of 14.6 months.
Most often, treatments such as surgery, chemotherapy, radiation, tumor treating fields therapy, or targeted therapy only slow progression...
The comment you're trying to see no longer exists.
Republic does not verify information provided by companies on this Portal and makes no assurance as to the completeness or accuracy of any such information. Additional information about companies fundraising on the Portal can be found by searching the EDGAR database.